However, we recently demonstrated that, in our in vitro non small cell lung cancer (NSCLC) model of acquired resistance to erlotinib and gefitinib, treatment with several agents known to target directly or indirectly the AKT signalling pathway, such ad LY294002, deguelin and everolimus, was not efficacious in inhibiting erlotinib- (ERL-) and gefitinib- (GEF-) resistant cancer cell proliferation [5]. The gene discussed is AKT1; the disease is cancer.